Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines (NASDAQ: PRAX) announced an expert fireside chat on November 24, 2025 at 1:00 PM EST to discuss a deep dive into clinical data for ulixacaltamide.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX) announced an expert fireside chat on November 24, 2025 at 1:00 PM EST to discuss a deep dive into clinical data for ulixacaltamide. The event will be hosted by HC Wainwright analyst Doug Tsao and feature UCSF statistician Prof. Chuck McCullough alongside Praxis CEO Marcio Souza. The session focuses on interpretation of ulixacaltamide clinical results and will include an analyst-led discussion; registration is available via the company’s provided link.
Details
News Market Reaction – PRAX
On Nov 21, the first trading day after this news, PRAX closed 3.48% above the previous close. That session’s volume was 2.1x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Nov 21 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that HCWainwright analyst Doug Tsao will host an expert call on Deep Dive into Praxis’ Ulixacaltamide Data with statistician Prof. Chuck McCullogh, University of California, San Francisco on November 24, 2025 at 1:00pm EST which will be joined by Marcio Souza, Praxis’ CEO.
The registration link can be found here.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.